Skip to main content
. 2022 Jul 25;12:885236. doi: 10.3389/fonc.2022.885236

Figure 5.

Figure 5

Prognostic impact of combined EGFR and CD3 expression in OSCCs. (A): Shown are percentages of tumors with CD3+ and CD3- expression based on EGFR status. (B, C): Shown are Kaplan-Meier estimates of overall survival of CD3+ and CD3- patients based on EGFR+ (B) or EGFR- (C) tumor expression. HR, hazard ratio; CI: 95% confidence interval.